COVID-19 vaccine effectiveness
(Randomized evidence)
Search studies
Trial | Type | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
---|---|---|---|---|---|---|---|---|
Intervention 1 | Intervention 2 | |||||||
NCT04651790 Sinovac Research and Development Co., Ltd Bueno S, Clin Infect Dis, 2021 Full text Commentary Commentary |
Inactivated virus |
CoronaVac 3 mcg D0/14 |
Adjuvant D0/14 |
RCTPhase 3 | Adult healthcare workers with no history of confirmed symptomatic SARS-CoV-2 infection who were in contact with possible or confirmed cases of COVID-19 in 8 sites in Chile. | N= 434 |
Some concerns Details |
|
NCT04508075 ; INA-WXFM0YX Sinovac Research and Development Co., Ltd Fadlyana E, Vaccine, 2021 Full text Commentary |
Inactivated virus |
CoronaVac |
Placebo |
RCTPhase 3 | Healthy adults aged 18 - 59 years, seropositive and seronegative, at a single center in Indonesia | N= 1620 |
Some concerns Details |
|
NCT04551547 Sinovac Research and Development Co., Ltd Han B, Lancet Infect Dis, 2021 Full text (21)00319-4/fulltext; Full text Commentary |
Inactivated virus |
CoronaVac 1.5 mcg D0/28 CoronaVac 3 mcg D0/28 |
Adjuvant |
RCTPhase 1/2 | Healthy children and adolescents aged 3-17 years with no history of SARS-CoV-2 infection in a single centre in China. | N= 552 |
Some concerns Details |
|
NCT04456595 Sinovac Research and Development Co., Ltd Palacios R, SSRN, 2021 PROFISCOV Full text Commentary |
Inactivated virus |
CoronaVac 3mcg D0/14 |
Adjuvant D0/14 |
RCTPhase 3 | Healthcare professionals with or without previous COVID-19 infection caring for COVID-19 patients at 16 centers in Brazil. | N= 12408 |
Some concerns Details |
|
NCT04582344 Sinovac Research and Development Co., Ltd Tanriover M, Lancet , 2021 Full text Commentary Commentary |
Inactivated virus |
CoronaVac |
Adjuvant |
RCTPhase 3 | Healthy healthcare workers and adults aged 18–59 years with no history of COVID-19 from 24 centres in Turkey | N= 10218 |
Some concerns Details |
|
NCT04383574 Sinovac Research and Development Co., Ltd Wu Z, Lancet Infect Dis, 2021 Full text Commentary ; Commentary |
Inactivated virus |
CoronaVac, 1.5mcg virus material inactivated SARS-CoV-2 whole virion vaccine, day 0/28 CoronaVac, 3mcg virus material inactivated SARS-CoV-2 whole virion vaccine, day 0/28 CoronaVac, 6mcg virus material inactivated SARS-CoV-2 whole virion vaccine, day 0/28 |
Adjuvant (Aluminum hydroxide) |
RCTPhase 1/2 | Healthy adults aged 60 years and older with no history of SARS-CoV-2 infection in a single centre in China | N= 422 |
Some concerns Details |
|
NCT04352608 Sinovac Research and Development Co., Ltd Zhang Y, Lancet Infect Dis, 2020 Full text Commentary ; Commentary |
Inactivated virus |
CoronaVac 6 mcg D0/28 CoronaVac 3 mcg D0/28 CoronaVac 6 mcg D0/14 CoronaVac 3 mcg D0/14 |
Adjuvant |
RCTPhase 1 | Healthy SARS-CoV-2 serology/DNA negative adults in a single centre in China | N= 144 |
Some concerns Details |
|
NCT04352608 Sinovac Research and Development Co., Ltd Zhang Y, Lancet Infect Dis, 2020 Full text Commentary ; Commentary |
Inactivated virus |
CoronaVac 3 mcg D0/14 CoronaVac 6 mcg D0/14 CoronaVac 3 mcg D0/28 CoronaVac 6 mcg D0/28 |
Adjuvant |
RCTPhase 2 | Healthy SARS-CoV-2 serology/DNA negative adults in a single centre in China | N= 600 |
Some concerns Details |